NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
The expansion makes Exothera one of the largest viral vector facilities in Europe
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Subscribe To Our Newsletter & Stay Updated
